((自动化翻译由路透提供,请见免责声明 ))
路透9月13日 - 正在开发基于免疫学疗法的 Zenas BioPharma 公司周四表示,它在美国的首次公开募股已筹集到 2.25 亿美元。
这家处于临床阶段的公司由制药商百时美施贵宝(Bristol -Myers Squibb ) 提供支持,其发行的1320万股股票定价为每股17美元,是其每股16至18美元目标区间的中点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.